scanX
Home
Granules

Granules

530.55
-4.75
(-0.89%)
search
ann
Q4 Quarterly Results are out. Check out the updated financials17 hours ago
Viewcross
right
Market Cap
12,980.70 Cr
EPS
16.73
PE Ratio
27.08
Dividend Yield
0.28 %
Industry
Healthcare
52 Week High
721.00
52 Week Low
401.25
PB Ratio
3.49
Debt to Equity
0.40
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Granules India: Gagillapur Facility to Resume Normal Operations by Q3Today
Granules India expects to resume normal operations at its Gagillapur facility by Q3 FY2025-26, following ongoing remediation efforts. The company plans to request FDA re-inspection around August. Despite current issues, production is gradually ramping up, and recent US product launches and the new GLS facility are helping offset shortfalls.
positive
Granules India Reports Q4 and FY25 Financial Performance2 days ago
Granules India has reported its financial performance for Q4 and FY25. The company achieved an EBITDA margin of 21% for FY25, which is within their guidance range of 20-22%. Additionally, Granules India's revenue share from North America increased to 79% in Q4FY25, compared to 70% in Q4FY24.
neutral
Granules India: Q4 Results Show Flat Sales, Narrowing Margins2 days ago
Granules India reported Q4 results with revenue up 1.8% YoY to ₹1,197.5 crore. EBITDA declined 1.4% YoY to ₹252 crore, with margins narrowing to 21.1%. Net profit increased 18% YoY to ₹152 crore. The company's Gagillapur facility received a USFDA warning letter in February.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,677.60
#1 4,07,839.00
35.55
#1 49,887.20
12.06
#1 9,648
-18.99
42.28
Divis Laboratories
6,612.00
1,76,045.50
80.38
8,184.00
0.89
1,600
23.05
63.47
Cipla
1,465.70
1,19,276.70
22.62
26,520.70
14.17
4,155
30.28
44.20
Torrent Pharmaceuticals
3,174.70
1,06,986.00
55.56
10,785.70
11.59
1,656
10.91
44.55
Dr Reddys Laboratories
1,251.20
1,04,156.70
#1 18.42
28,905.40
12.36
5,578
21.14
67.52
Mankind Pharma
2,467.70
1,01,568.60
51.21
10,615.60
19.57
1,942
-10.91
48.86
Zydus Life Science
930.00
93,051.50
19.92
19,831.50
13.82
3,831
-0.19
63.14
Lupin
1,957.70
89,943.10
27.40
20,141.50
#1 19.94
1,936
#1 112.49
43.05
Aurobindo Pharma
1,147.80
68,122.20
19.71
29,559.20
17.55
3,169
-0.50
43.00
Abbott
30,455.00
64,491.60
45.58
6,097.20
10.80
1,201
27.83
50.48
Forecast
Actual
Growth Rate
Revenue Growth
-0.33 %
Net Income Growth
-21.54 %
Cash Flow Change
-40.52 %
ROE
-31.01 %
ROCE
-21.01 %
EBITDA Margin (Avg.)
-6.98 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
357
324
354
326
372
347
362
357
356
382
404
417
517
483
598
640
634
623
708
708
682
741
861
861
803
858
893
1,002
1,034
1,024
1,156
1,147
1,199
984
1,190
1,150
1,171
1,171
960
1,139
1,230
Expenses
306
260
284
260
292
275
284
277
278
302
316
337
460
381
480
519
516
477
556
573
500
552
602
633
597
648
737
823
837
808
908
915
967
849
977
905
920
921
763
907
945
EBITDA
51
64
69
67
81
72
78
81
79
80
89
80
57
102
118
121
119
146
152
135
182
189
260
228
205
209
156
179
197
216
248
232
232
135
213
245
251
251
197
232
284
Operating Profit %
14 %
19 %
19 %
20 %
21 %
20 %
21 %
22 %
22 %
20 %
20 %
18 %
9 %
16 %
17 %
18 %
16 %
20 %
21 %
19 %
17 %
25 %
30 %
25 %
25 %
24 %
17 %
17 %
19 %
21 %
21 %
20 %
19 %
14 %
18 %
21 %
21 %
21 %
20 %
20 %
21 %
Depreciation
14
14
14
15
15
16
19
19
18
18
19
20
20
25
27
27
27
29
30
39
39
34
36
37
45
39
40
39
40
43
44
48
49
49
53
52
53
53
53
57
64
Interest
8
8
9
10
9
8
8
8
8
8
10
8
6
7
8
8
7
7
7
7
7
6
6
7
7
7
6
5
6
7
13
17
19
23
26
29
29
27
26
27
24
Profit Before Tax
29
42
46
42
56
47
51
54
53
55
60
52
30
71
84
87
84
110
115
89
137
149
217
184
154
163
110
135
150
166
190
167
164
66
136
170
176
181
128
153
198
Tax
7
14
14
13
23
8
11
15
7
18
19
17
10
19
23
27
20
27
19
25
44
38
54
37
26
43
30
34
39
38
45
43
44
18
34
45
46
47
31
35
46
Net Profit
22
29
32
29
33
39
41
39
46
37
40
35
20
52
60
60
64
83
96
64
92
111
164
147
128
120
81
101
111
128
145
124
120
48
102
126
130
135
97
118
152
EPS in ₹
1.10
1.40
1.58
1.42
1.60
1.80
1.88
1.79
2.09
1.61
1.76
1.38
0.81
2.04
2.37
2.37
2.52
3.27
3.77
2.52
3.63
4.39
6.60
5.92
5.15
4.85
3.26
4.07
4.48
5.14
5.85
5.11
4.94
1.98
4.22
5.18
5.35
5.56
4.01
4.85
6.27
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
1,203
1,563
1,879
2,677
2,983
3,228
3,714
4,513
4,905
5,521
Fixed Assets
617
560
644
777
944
1,204
1,332
1,541
1,911
2,096
Current Assets
500
818
828
1,187
1,282
1,629
1,997
2,505
2,574
2,905
Capital Work in Progress
62
77
267
515
496
294
239
356
239
272
Investments
0
70
108
157
210
19
19
20
21
22
Other Assets
524
856
859
1,229
1,332
1,711
2,123
2,596
2,733
3,132
Total Liabilities
1,203
1,563
1,879
2,677
2,983
3,228
3,714
4,513
4,905
5,521
Current Liabilities
415
655
787
878
897
893
1,173
1,642
1,814
2,082
Non Current Liabilities
357
247
188
495
557
491
367
284
256
213
Total Equity
431
662
904
1,304
1,530
1,844
2,173
2,587
2,835
3,226
Reserve & Surplus
411
613
881
1,279
1,504
1,818
2,149
2,562
2,811
3,201
Share Capital
20
22
23
25
25
25
25
25
24
24
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
24
75
-82
66
-25
103
-144
143
107
90
Investing Activities
-146
-162
-326
-462
-270
-160
-277
-379
-192
-358
Operating Activities
150
151
188
-1
262
476
433
332
739
439
Financing Activities
19
86
56
529
-17
-213
-299
190
-440
8
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
42.04 %
42.04 %
42.04 %
41.98 %
41.98 %
41.98 %
41.93 %
42.02 %
42.02 %
42.02 %
42.02 %
41.96 %
41.96 %
41.96 %
38.87 %
38.87 %
38.85 %
38.84 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
19.57 %
20.39 %
19.49 %
15.87 %
15.15 %
DIIs
1.50 %
2.86 %
2.77 %
4.34 %
3.97 %
3.03 %
4.32 %
4.23 %
4.76 %
5.03 %
6.68 %
6.85 %
10.14 %
10.70 %
14.12 %
14.86 %
19.57 %
22.45 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
26.21 %
29.74 %
27.00 %
24.99 %
24.55 %
25.26 %
21.72 %
21.60 %
20.74 %
21.13 %
21.91 %
21.11 %
20.39 %
19.38 %
18.78 %
18.29 %
17.45 %
16.07 %
Others
30.26 %
25.36 %
28.19 %
28.69 %
29.49 %
29.73 %
32.03 %
32.15 %
32.49 %
31.82 %
29.39 %
30.07 %
27.51 %
8.39 %
7.84 %
8.49 %
8.27 %
7.50 %
No of Share Holders
0
1,93,871
2,61,165
2,39,520
2,16,385
2,10,785
2,14,539
2,16,055
2,02,329
1,90,894
2,01,054
2,07,055
1,90,691
1,82,142
1,79,870
2,02,198
1,77,554
1,69,802

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.9 1 1 1 1.5 1.5 1.5 1.5 0.00
Dividend Yield (%) 0.00 0.87 0.87 0.7 0.33 0.49 0.52 0.35 0.31 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
07 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 07 Aug 2025 528.85 535.15
28 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 28 May 2025 448.15 528.85
24 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 24 Jan 2025 616.75 599.30
06 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 Nov 2024 608.95 550.65
06 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 06 Aug 2024 399.75 641.55
30 Jul 2024 DIVIDEND Dividend
₹ 1.50 /share
 30 Jul 2024 399.75 564.85
03 Aug 2023 DIVIDEND Dividend
₹ 1.50 /share
 03 Aug 2023 292.80 317.15
21 Jul 2022 DIVIDEND Dividend
₹ 0.75 /share
 19 Jul 2022 250.75 308.10
18 Feb 2022 DIVIDEND Dividend
₹ 0.25 /share
 17 Feb 2022 312.00 305.70
25 Nov 2021 DIVIDEND Dividend
₹ 0.25 /share
 24 Nov 2021 317.10 312.65
06 Aug 2021 DIVIDEND Dividend
₹ 0.25 /share
 05 Aug 2021 377.45 386.30
30 Jul 2021 DIVIDEND Dividend
₹ 0.75 /share
 28 Jul 2021 364.15 371.45
09 Feb 2021 DIVIDEND Dividend
₹ 0.25 /share
 08 Feb 2021 355.30 331.95

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome1 day ago
Record Date For Payment Of Final Dividend For FY252 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation2 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
Audited Financial Results For The Quarter And Financial Year Ended On March 31 20252 days ago
Outcome Of The Board Meeting2 days ago
Board Meeting Outcome for Outcome Of The Board Meeting2 days ago
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 07, 2025
Board Meeting Intimation for Consideration And Approval Of The Audited Financial Results For The FY Ended March 31 2025 And Recommendation Of Final Dividend If Any.May 07, 2025
Announcement under Regulation 30 (LODR)-Change in Registered Office AddressApr 20, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 10, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 07, 2025
Closure of Trading WindowMar 27, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 25, 2025
Board Meeting Outcome for Outcome Of The Board MeetingMar 25, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 20, 2025
UpdateMar 18, 2025
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Mar 03, 2025
Update Under Regulation 30Feb 28, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 28, 2025
UpdatesFeb 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 21, 2025
Board Meeting Outcome for Outcome Of The Board MeetingFeb 21, 2025
UpdateFeb 07, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 30, 2025
Transcript Of Earnings Conference Call For Q3 Of FY25Jan 30, 2025
UpdateJan 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Integrated Filing (Financial)Jan 24, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 24, 2025
Un-Audited Financial Results For The Quarter & Nine-Months Ended On December 31 2024Jan 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 09, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 09, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2024.Jan 08, 2025
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 17, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 17, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 10, 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 09, 2024
UpdateDec 04, 2024
UpdateDec 03, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementDec 02, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 27, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 14, 2024
Transcript Of The Earnings Conference Call For Q2 And Half Year Of FY25.Nov 13, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 08, 2024

Technical Indicators

RSI(14)
Neutral
69.40
ATR(14)
Volatile
16.01
STOCH(9,6)
Overbought
85.37
STOCH RSI(14)
Overbought
94.59
MACD(12,26)
Bullish
4.36
ADX(14)
Strong Trend
33.37
UO(9)
Bearish
58.66
ROC(12)
Uptrend But Slowing Down
8.62
WillR(14)
Overbought
-11.03
Bearish
5
Neutral
2
Bullish
2

Mutual Fund Holdings

Funding HouseNo of SharesCurrent Holding %1M Change %3M Change %Month
Old Bridge Focused Equity Fund Direct - Growth
696000
2.17%
-0.38%
-0.62%
Apr 2025
Mirae Asset Arbitrage Fund Direct - Growth
0
0.00%
-0.28%
-0.28%
Apr 2025
Motilal Oswal Arbitrage Fund Direct-Growth
18000
0.12%
-0.21%
0.12%
Apr 2025
ITI Pharma and Healthcare Fund Direct - Growth
87650
1.82%
-0.17%
-0.20%
Apr 2025
Axis Value Fund Direct-Growth
236697
1.26%
-0.15%
-0.21%
Apr 2025
Aditya Birla Sun Life Pure Value Direct Fund-Growth
2664920
2.08%
-0.15%
-0.13%
Apr 2025
Axis India Manufacturing Fund Direct-Growth
1749620
1.49%
-0.12%
-0.29%
Apr 2025
Axis Multicap Fund Direct-Growth
1729416
1.09%
-0.12%
-0.17%
Apr 2025
Tata Hybrid Equity Fund Direct Plan-Growth
1100000
1.25%
-0.11%
-0.11%
Apr 2025
Tata Midcap Growth Direct Plan-Growth
1000767
1.01%
-0.11%
-0.16%
Apr 2025
Aditya Birla Sun Life Small Cap Fund Direct-Growth
1106670
1.11%
-0.11%
-0.15%
Apr 2025
HSBC Arbitrage Fund Direct-Growth
65000
0.13%
-0.10%
-0.08%
Apr 2025
Tata Large Cap Direct Plan-Growth
533136
0.96%
-0.10%
-0.13%
Apr 2025
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0
0.00%
-0.10%
-0.10%
Apr 2025
HDFC Arbitrage Fund Wholesale Direct-Growth
238000
0.06%
-0.09%
-0.09%
Apr 2025
ITI Mid Cap Fund Direct - Growth
187476
0.76%
-0.08%
-0.12%
Apr 2025
Edelweiss Balanced Advantage Fund Direct-Growth
2500000
0.91%
-0.08%
-0.07%
Apr 2025
ICICI Prudential Nifty Pharma Index Fund Direct - Growth
15581
0.85%
-0.08%
-0.10%
Apr 2025
Aditya Birla Sun Life Special Opportunities Fund Direct-Growth
137315
0.83%
-0.08%
-0.10%
Apr 2025
Parag Parikh Arbitrage Fund Direct - Growth
146000
0.47%
-0.08%
-0.06%
Apr 2025
Aditya Birla Sun Life Multi-Cap Fund Direct-Growth
1038748
0.78%
-0.08%
-0.11%
Apr 2025
Tata Nifty MidSmall Healthcare Index Fund Direct - Growth
35527
1.20%
-0.08%
-0.17%
Apr 2025
Edelweiss Aggressive Hybrid Fund Direct - Growth
335000
0.58%
-0.07%
-0.09%
Apr 2025
Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth
6389
1.20%
-0.07%
-0.15%
Apr 2025
Nippon India Arbitrage Fund Direct-Growth
953000
0.31%
-0.07%
-0.04%
Apr 2025

About Granules

Granules India Limited is a vertically integrated pharmaceutical company founded in 1991. It manufactures Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company specializes in off-patent drugs and first-line defense products like Paracetamol, Ibuprofen, Metformin, and Guaifenesin. Granules India operates seven manufacturing facilities, six in India and one in the US, serving over 300 customers across 80 countries. The company has a strong focus on research and development, with a dedicated R&D center in Hyderabad. Granules India has expanded its operations through acquisitions, capacity enhancements, and the establishment of subsidiaries. It has received various regulatory approvals and certifications for its facilities and products. The company has filed numerous ANDAs, DMFs, and CEPs, and has launched several generic products in the US market.
Website
https://www.granulesindia.com
Chairperson NameC Krishna Prasad
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Intraday Screeners
Technical Screeners
Fundamental Screeners
Candlestick Screeners
Price & Volume Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Corporate Office: A-302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai – 400066, Maharashtra, India. Land Line: 022-43116666.